Levicept has a highly experienced Board and Senior Management Team with extensive experience in pharmaceutical and biotechnology companies. Furthermore, Levicept has brought together a multidisciplinary team of pharmaceutical consultants to complement its own core internal expertise to assist in the development of p75NTR-Fc.
Simon Westbrook - CEO and Founder
Simon has a strong track record of innovation and delivery of drug development programmes with 20 years of drug discovery and development experience, including 15 years at Pfizer Sandwich UK. Simon has played pivotal roles in progressing novel, successful projects from conception of idea to delivery of clinical data. Simon is the named inventor on numerous patents, including p75NTR-Fc for the treatment of pain. He was a team member of four programmes that achieved positive readout in proof-of-concept phase II clinical trials, of which he is the co-inventor of three.
Kevin Johnson - Executive Chairman
Kevin has been working with Index Ventures since 2003, focusing on drug development companies, including Acutus Inc, B3NGF and Levicept . Prior to joining Index, Kevin was CEO of PanGenetics, an antibody development company and Index investment that was acquired by Abbott. During his career at Cambridge Antibody Technology (CAT), including Head of Research and board membership as Research Director and Chief Technology Officer, he led development of CAT’s platform technologies and their application in the discovery of a number of antibodies currently in clinical development. Two of these, Humira (Abbott Pharmaceutical) and Benlysta (GlaxoSmithKline), are now on the market.
Raj is a general partner at Advent, having joined in 2005. He has over 20 years of experience as an entrepreneur and investor in the life sciences. He has served on the Board of several Advent portfolio companies including Thiakis, Avila, EUSA and Cellnovo.
David is a Venture Partner in the life sciences team and Index Ventures. He founded Funxional Therapeutics and XO1 and on behalf of Index Ventures, co-founded E3Bio, Methusalah, Purple therapeutics and Stx Pharma.
Arthur Franken has been a partner at Gilde Healthcare since 2001. He is a member of the Supervisory Board of Moximed, ProQR Therapeutics Symphogen and was a member of the Supervisory Board of FlowCardia and MTM Laboratories.